SRT3 📈 Sartorius Aktiengesellschaft - Overview

Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE0007165631

SRT3: Bioreactors, Fermenters, Filtration, Pipettes, Chromatography, Balances, Software

Sartorius Aktiengesellschaft is a leading provider of bioprocess solutions and lab products, catering to a diverse range of industries, including life science research, biopharmaceutical manufacturing, and pharmaceutical quality control. The company's extensive product portfolio encompasses a broad spectrum of equipment and services, including bioreactors, fermenters, cell culture media products, and fluid management systems. These solutions are designed to facilitate the development and production of biopharmaceuticals, vaccines, and other biological products. Additionally, Sartorius offers a range of lab products, such as pipettes, pipette tips, and lab balances, which are essential for various laboratory applications.

The company's product line also includes advanced technologies, such as live-cell analysis systems, reagents, and consumables, which enable researchers to study cellular behavior and interactions. Furthermore, Sartorius provides contract manufacturing and integration services, allowing customers to outsource specific processes and focus on their core activities. The company's process automation platform, software, and data analytics tools help customers optimize their workflows, improve efficiency, and reduce costs. Sartorius also offers a range of chromatography consumables, columns, and systems, which are used in various applications, including biopharmaceutical development and quality control.

Sartorius Aktiengesellschaft has a long history, dating back to 1870, and is headquartered in Göttingen, Germany. The company has established itself as a trusted partner for the life science industry, providing innovative solutions and services that support the development of new therapies and treatments. With a strong focus on research and development, Sartorius continues to expand its product portfolio and services, addressing the evolving needs of its customers. The company's commitment to quality, reliability, and customer satisfaction has earned it a reputation as a leading provider of bioprocess solutions and lab products.

In addition to its product offerings, Sartorius provides a range of services, including bioprocess consulting and engineering, biologics testing, and validation services. These services are designed to support customers in optimizing their bioprocesses, ensuring compliance with regulatory requirements, and improving overall efficiency. The company's expertise in bioprocess development, scale-up, and manufacturing enables it to provide valuable guidance and support to its customers. With its comprehensive portfolio of products and services, Sartorius Aktiengesellschaft is well-positioned to meet the needs of the life science industry, both now and in the future.

The company's customer base is diverse, encompassing pharmaceutical and biotechnology companies, research institutions, and applied industries. Sartorius' solutions are used in various applications, including cell and gene therapy, vaccine development, and biopharmaceutical manufacturing. The company's products and services are designed to support the entire bioprocess workflow, from early-stage research to commercial-scale manufacturing. With its strong industry expertise and commitment to innovation, Sartorius Aktiengesellschaft is a trusted partner for companies and organizations seeking to advance the development of new therapies and treatments.

Additional Sources for SRT3 Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

SRT3 Stock Overview

Market Cap in USD 14,873m
Sector Healthcare
Industry Medical Instruments & Supplies
GiC Sub-Industry Health Care Equipment
IPO / Inception

SRT3 Stock Ratings

Growth 5y -15.6%
Fundamental 32.2%
Dividend 52.8%
Rel. Strength Industry -1731
Analysts -
Fair Price Momentum 185.92 EUR
Fair Price DCF 330.61 EUR

SRT3 Dividends

Dividend Yield 12m 0.34%
Yield on Cost 5y 0.39%
Annual Growth 5y 18.36%
Payout Consistency 96.2%

SRT3 Growth Ratios

Growth Correlation 3m -73.9%
Growth Correlation 12m -80.7%
Growth Correlation 5y -25.8%
CAGR 5y 2.30%
CAGR/Mean DD 5y 0.08
Sharpe Ratio 12m -0.82
Alpha -60.01
Beta 0.84
Volatility 41.14%
Current Volume 153k
Average Volume 20d 85.8k
What is the price of SRT3 stocks?
As of December 21, 2024, the stock is trading at EUR 215.60 with a total of 153,007 shares traded.
Over the past week, the price has changed by -6.78%, over one month by +3.35%, over three months by -12.90% and over the past year by -38.03%.
Is Sartorius Aktiengesellschaft a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Sartorius Aktiengesellschaft is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 32.22 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SRT3 as of December 2024 is 185.92. This means that SRT3 is currently overvalued and has a potential downside of -13.77%.
Is SRT3 a buy, sell or hold?
Sartorius Aktiengesellschaft has no consensus analysts rating.
What are the forecast for SRT3 stock price target?
According to ValueRays Forecast Model, SRT3 Sartorius Aktiengesellschaft will be worth about 202.5 in December 2025. The stock is currently trading at 215.60. This means that the stock has a potential downside of -6.1%.
Issuer Forecast Upside
Wallstreet Target Price 264.4 22.6%
Analysts Target Price - -
ValueRay Target Price 202.5 -6.1%